HealthEconomics.Com

Connected. Community.

  • facebook
  • linkedin
  • twitter
  • vimeo
  • rss
  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • Value, Evidence & Access Marketplace
    • About the Marketplace
    • Visit the Marketplace
    • On-demand Webinar
    • Find Out More
  • Industry Events
    • Conferences
    • Webinars
    • HealthEconomics.Com On-demand Webinars
    • Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists
      • Podcasts
Home » News » Analyst: Amgen, Teva Price Hikes Not Forced by PBMs, Rebates

Analyst: Amgen, Teva Price Hikes Not Forced by PBMs, Rebates

Bernstein Analyst Ronny Gal says there are solid data points which provide a foundation for the argument some drug companies raise prices “because they can,” not because they’re working to keep up with pharmacy benefit managers (PBM) and rebates.

Drugs.MoneyAccording to a report by Gal, Amgen increased the price of Blincyto twice so far this year. The first price hike to the tune of 4 percent was implemented in January, with a second 3.9 percent increase in late June. The cost has risen by roughly 8 percent since the start of the year.

Teva also raised the price on its Treanda twice so far this year. The cost of Treanda rose by 3 percent in January and 4.5 percent July 1, for a total price increase of roughly 7.5 percent since January 1.

According to a FiercePharma report, both drugs treat variations of leukemia. Treanda also treats non-Hodgkin lymphoma.

A spokesperson with Teva said the price of Treanda is “reflective of the value it provides to patients, providers and patients in the treatment of [chronic lymphocytic leukemia] and [non-Hodgkin lymphoma] that has progressed.” The drug also comes out a 50 percent discount, the spokesperson said, for patients who receive treatment at hospitals impacted by a government discount program.

Amgen reportedly did not respond to FiercePharma’s request for comment.

“Noticec that in this segment, where rebates are uncommon, drug companies continue to price up at high single digits,” Gal wrote. “This is the strongest data point for those who argue drug companies raise prices ‘because they can’ and not because they are forced to do so by PBMs.”

Click here to read the full report on FiercePharma’s website.



You might also be interested in:

  • Real-World Evidence 2022: Rare Diseases and Innovative Therapies 02/15/2022
  • Drug Makers Raise Prices of Hundreds of Medications by 4.9% for 2022 01/04/2022
  • Influential Usage of Big Data and Artificial Intelligence in… 09/07/2021
  • Exploring Climate Change Through the Lens of Health Equity 05/25/2022
  • Price transparency for medicines could lead to a 12% price… 10/15/2021
  • PBM Transparency Reform Prompts New Coalition and Low-Cost Startups 11/09/2021
  • Opioid Manufacturer Teva Reaches $225 Million Settlement Deal… 02/17/2022

Advertise With Us!View All JobsPost a JobView Current NewsletterSubscribe to Newsletters
Webinar of the Week
Conference of the Week
Link of the Week

HealthEconomics.Com Jobs Portal

  • Manager, Statistical Analytics
  • Director / Senior Director, RWE
  • Research Analyst
  • Medical Writer
  • Associate Director/Director, Business Development
 
Syndicated Reports

Economic & Related Consulting Service Revenues World Report & Database

Healthcare Analytical Testing Services Market worth $9.8 billion by 2026 – Key Players are Eurofins Scientific, SGS S.A., Charles River Laboratories

Risk-Based Monitoring Software Market Worth $511 Million By 2025 – Growing Number Of Clinical Trials To Propel Market Growth

Real-World Evidence Solutions Market – Growth, Trends, COVID-19 Impact, and Forecasts (2021 – 2026)

 
White Papers

The Augmented Rep: A practical field force guide for the Omnichannel era

Rare Disease’s Star Turn

The Next Generation of Information Management

Risk Mitigation for Pharma Manufacturer Programs

HealthEconomics.Com

HealthEconomics.Com

  • News
  • Conferences
  • Reports
  • Jobs
  • Consulting
  • Newsletters
  • White Papers

More Links

  • Jobs
  • Education
  • Graduate Schools
  • Webinar Services

Support & Contact

  • Contact Us

About

  • About Us
  • Advertise
  • Webinar Services
  • HE Institute
  • Testimonials
  • Privacy Policy

Stay Connected

  • facebook
  • twitter
  • linkedin
  • pinterest
  • google-plus
  • youtube
  • rss

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities.

HEALTHECONOMICS HZ SMALL V2

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities, proving news, education, jobs, resources, policy updates, consulting, advertising, all available via website, newsletters, and social media.

© 2017 Health Economics. All rights reserved.

  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • Value, Evidence & Access Marketplace
    • About the Marketplace
    • Visit the Marketplace
    • On-demand Webinar
    • Find Out More
  • Industry Events
    • Conferences
    • Webinars
    • HealthEconomics.Com On-demand Webinars
    • Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists
      • Podcasts